Acute plasma amylase increase after glucagon-like peptide -1 receptor agonist exenatide administration in Type 2 diabetes

Diabet Med. 2017 Apr;34(4):591-592. doi: 10.1111/dme.13160.

Authors

M M Smits¹, L Tonneijck¹, M H A Muskiet¹, M Diamant¹, M H H Kramer¹, D L Cahen², D H van Raalte¹

Affiliations

¹ Diabetes Center, Department of Internal Medicine, VU University Medical Center, Amsterdam, The Netherlands.
² Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Amylases / blood*
Diabetes Mellitus, Type 2 / drug therapy*
Diabetes Mellitus, Type 2 / enzymology
Exenatide
Glucagon-Like Peptide-1 Receptor* / agonists
Humans
Hypoglycemic Agents*
Lipase / blood
Middle Aged
Peptides / adverse effects*
Peptides / therapeutic use*
Randomized Controlled Trials as Topic
Venoms / adverse effects*
Venoms / therapeutic use*

Substances

Glucagon-Like Peptide-1 Receptor
Hypoglycemic Agents
Peptides
Venoms
Exenatide
Lipase
Amylases